Sign in

AAPG on Nasdaq

ASCENTAGE PHARMA GROUP INTERNATIONAL

ASCENTAGE PHARMA GROUP INTERNATIONAL is a pharmaceutical preparations company in the Cayman Islands.1 Its shares trade on Nasdaq under the symbol AAPG.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with LIFECORE BIOMEDICAL, INC. \DE\, Xencor Inc or Karyopharm Therapeutics Inc., or pick any stock.

  • TickerAAPG on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersE91
  • Incorporated inCayman Islands2
  • Business address68 Xinqing Road, Suzhou Industrial Park, Suzhou , Jiangsu2
  • Filer categoryNon-accelerated filer, Emerging growth company2

See how the biggest companies compare on our leaderboards

2009. Dr. Yang, Dr. Zhai, Dr. Wang and Dr. Guo, our co-founders, were the initial majority shareholders of Ascentage Pharma (HK).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

97.0%Gross margin4
-41.4%Net margin4
-148.0%Return on equity4
3.24×Debt to equity4
-$18.6MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Products brought in 87% of the revenue ASCENTAGE PHARMA GROUP INTERNATIONAL broke down this way in fiscal 2025.

  1. Products499.3M CNY587%up 91% from 2024
  2. Others74.8M CNY513%up 81% from 2024
Products and services by year
Products and services202320242025
Products193.5M CNY260.8M CNY499.3M CNY
Others28.4M CNY41.4M CNY74.8M CNY

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue3¢$4.0M
  • Research and development90¢$129.8M
  • Interest6¢$8.8M
  • Income tax1¢$1.4M

Out of $134.3M in revenue.4 The company lost money this year.

Financial statements

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Total revenue574.1M CNY980.6M CNY222.0M CNY
Total cost of sales-48.9M CNY-29.1M CNY-30.5M CNY
Gross profit525.2M CNY951.6M CNY191.4M CNY
Other income and gains103.5M CNY57.4M CNY59.3M CNY
Selling and distribution expenses-353.6M CNY-196.0M CNY-195.4M CNY
Administrative expenses-246.3M CNY-187.1M CNY-181.1M CNY
Research and development expenses-1.1B CNY-947.2M CNY-707.0M CNY
Other expenses-73.6M CNY-9.1M CNY-5.2M CNY
Finance costs-54.1M CNY-64.5M CNY-96.1M CNY
Share of profit/(loss) of a joint venture314.0K CNY-281.0K CNY1.1M CNY
LOSS BEFORE TAX-1.2B CNY-395.3M CNY-932.9M CNY
Income tax credit/(expense)-6.9M CNY-10.4M CNY7.2M CNY
LOSS FOR THE YEAR-1.2B CNY-405.7M CNY-925.7M CNY
Ordinary equity holders of the Company-1.2B CNY-405.4M CNY-925.6M CNY
Non-controlling interests-218.0K CNY-247.0K CNY-75.0K CNY
Basic (in Dollars per share and Yuan Renminbi per share)-3.49 CNY-1.34 CNY-3.28 CNY
Diluted (in Dollars per share and Yuan Renminbi per share)-3.49 CNY-1.34 CNY-3.28 CNY

Compare ASCENTAGE PHARMA GROUP INTERNATIONAL with another company

What it owns

What ASCENTAGE PHARMA GROUP INTERNATIONAL reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$116.4M4 Dec 31, 2024
Operating-lease assets (leased space)$7.7M4 Dec 31, 2024$7.0M4 Dec 31, 2023+9.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$122.4M4 Dec 31, 2024$142.2M4 Dec 31, 2023−14.0%
Long-term investments$150.1M4 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$3.4M4 Dec 31, 2024

Inventory

ItemLatestA year beforeChange
Inventory, total$904.0K4 Dec 31, 2024

Leadership

Who has led ASCENTAGE PHARMA GROUP INTERNATIONAL, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dajun Yang2026–now

Chair

  1. Dajun Yang2026–now

Chief financial officer

  1. Veet Misra2026–now
Board members and other officers (10)

Timeline

  1. Mar 19, 2026New chief executive Dajun Yang becomes CEO6

Calendar

Drug trials and FDA: coming up

  1. Dec 31, 2026Phase 3 trial readout expected Phase 3 trial of lisaftoclax +BTK inhibitor and BTK inhibitor in CLL/SLL: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT06104566).18
  2. Dec 2026Phase 2 trial readout expected Phase 2 trial of APG2575 in Chronic Lymphocytic Leukemia: primary completion expected Dec 2026 (ClinicalTrials.gov NCT05147467).19
  3. Mar 31, 2027Phase 3 trial readout expected Phase 3 trial of Olverembatinib in GIST: primary completion expected Mar 31, 2027 (ClinicalTrials.gov NCT06640361).20
  4. Jun 1, 2027Phase 1/2 trial readout expected Phase 1/2 trial of APG-115 and APG-2575 in Neuroblastoma: primary completion expected Jun 1, 2027 (ClinicalTrials.gov NCT05701306).21
  5. Jun 30, 2027Phase 3 trial readout expected Phase 3 trial of olverembatinib and Bosutinib in Chronic Myeloid Leukemia: primary completion expected Jun 30, 2027 (ClinicalTrials.gov NCT06423911).22
  6. Aug 2027Phase 3 trial readout expected Phase 3 trial of Lisaftoclax (APG-2575), Acalabrutinib and others in CLL/SLL: primary completion expected Aug 2027 (ClinicalTrials.gov NCT06319456).23

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

129 filings to the SEC since October 2021: 2 annual reports, 26 insider forms, 101 other. The latest 20:

  1. Oct 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Sep 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Sep 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Aug 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Aug 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Aug 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Aug 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. Jul 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Jul 20, 2026F-3ASR REGISTRATION STATEMENT EDGAR
  11. Jul 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. Jun 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Jun 29, 20263 PRIMARY DOCUMENT EDGAR
  14. Jun 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Jun 12, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Jun 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Jun 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. May 28, 20266-K CURRENT REPORT EDGAR
  19. May 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. May 22, 20264 PRIMARY DOCUMENT EDGAR

The 129 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Point72 Asset Management, L.P.13,841$243.0K0.0%−2,215
Morgan Stanley919$16.1K0.0%+421
Wells Fargo & Company/mn200$3.5K0.0%New
EverSource Wealth Advisors, LLC24$4210.0%No change
UBS Group AG15$2630.0%−109
BlackRock, Inc.6$1050.0%New
Caitong International Asset Management Co., Ltd1$180.0%New
Royal Bank Of Canada6$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How ASCENTAGE PHARMA GROUP INTERNATIONAL is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARASCENTAGE PHARMA GROUP INTERNATIONAL1
  • CIK0002023311
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company3
  • Incorporated inCayman Islands3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address68 Xinqing Road, Suzhou Industrial Park, Suzhou , Jiangsu, China1
  • Phone86 512 8555 77771
  • Shares outstanding373,322,192 shares as of Apr 1, 20263
  • AuditorErnst & Young Hua Ming LLP, China PCAOB ID 1408; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJun 14, 20241
  • Filings129 in all: 6-K (74), 3 (14), 3/A (9), DRS/A (4), 4 (3), DRSLTR (3), UPLOAD (3), 20-F (2)1
    All 21 form types

    6-K/A (2), CORRESP (2), S-8 (2), SEC STAFF LETTER (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), F-1 (1), F-1/A (1), F-3ASR (1), S-8 POS (1)

  • Latest filingsAnnual report (20-F) Apr 29, 2026

Securities registered for trading

ClassSymbolExchange
American depositary shares (each representing four ordinary shares, no par value per share)AAPGNasdaq

From the cover page of the 20-F filed Apr 29, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23